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Abstract
Objective Our objective was to compare therapeutic response among patients with early-onset psoriasis (EOP) and late-onset 
psoriasis (LOP) receiving adalimumab, etanercept, infliximab, ustekinumab, or methotrexate in the Psoriasis Longitudinal 
Assessment and Registry (PSOLAR).
Methods Patients were grouped by age of onset: EOP (age ≤ 40 years) or LOP (age > 40 years). Repeated-measures analysis 
with logistic regression was used to calculate the adjusted odds ratio (AOR; adjusted for baseline characteristics) for achiev-
ing a Physician’s Global Assessment score of cleared/minimal (PGA 0/1) or a percentage of body surface area involved with 
psoriasis < 3% (%BSA < 3) or %BSA < 1 for all patients; similar sensitivity analyses were performed for each treatment group.
Results Of 7511 patients, 5479 (72.9%) had EOP. The LOP group had a higher likelihood of achieving PGA 0/1 after treat-
ment than did the EOP group in all patients (AOR 1.14 [95% confidence interval (CI) 1.05–1.25]; p = 0.0019); the same 
was true in subgroups of etanercept-treated (AOR 1.38 [95% CI 1.14–1.66]; p = 0.0010) and methotrexate-treated (AOR 
1.62 [95% CI 1.16–2.26]; p = 0.0049) patients. No significant difference was found between the EOP and LOP groups with 
regard to the likelihood of achieving %BSA < 3 or %BSA < 1 among all patients. However, LOP patients were more likely 
than EOP patients to achieve %BSA < 3 or %BSA < 1 in subgroups treated with infliximab (AOR 1.45 [95% CI 1.09–1.93; 
p = 0.0103] and AOR 1.36 [95% CI 1.03–1.78; p = 0.0290], respectively) and etanercept (AOR 1.30 [95% CI 1.06–1.61; 
p = 0.0123] and AOR 1.34 [95% CI 1.09–1.64; p = 0.0053], respectively).
Conclusion Our real-world data from PSOLAR indicate that there are differences in some patient characteristics between 
EOP and LOP and that patients with EOP are less likely than those with LOP to respond to certain systemic treatments. 
(ClinicalTrials.gov identifier: NCT00508547).
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Key Points 
Based on a review of over 7500 patients enrolled in the 
PSOLAR registry, some disease characteristics may dif-
fer between early-onset psoriasis and late-onset psoriasis 
(aged ≤ 40 years and > 40 years, respectively).
Results of modeled analyses adjusted for differences in 
baseline characteristics showed that response to certain 
biologic agents, such as infliximab and etanercept, is bet-
ter in late-onset psoriasis than in early-onset psoriasis.
Age of onset may be an important consideration in 
developing individualized treatment regimens to maxi-
mize therapeutic response for patients with psoriasis.
1 Introduction
Psoriasis is a chronic, inflammatory skin condition that 
affects between 2 and 4% of the global population and 
varies widely between countries [1]. Psoriasis onset may 
occur at any age; however, some studies have demonstrated 
a bimodal distribution of age of onset in both male and 
female patients with psoriasis. One peak occurred at age 
16 years for females and 22 years for males, with another 
peak at age 60 years for females and 57 years for males [2]. 
Two subtypes of psoriasis have been identified based on 
age of onset: early-onset psoriasis (EOP; age ≤ 40 years) 
and late-onset psoriasis (LOP; age > 40 years) [2]. The 
dichotomizing of psoriasis patients into early versus late 
onset of disease is consistent with differences in genetic 
predisposition and clinical presentation.
Understanding the differences between these two sub-
types of psoriasis is important because they appear to mani-
fest with variable disease activity and may be associated 
with different patterns of disease. The landmark study by 
Henseler et al. [2] found that patients with EOP were more 
likely than those with LOP to experience frequent disease 
relapses (73 vs. 27%), extensive body surface involvement 
(75 vs. 25%), and nail involvement (74 vs. 26%). The authors 
also reported a higher prevalence of EOP versus LOP when 
stratified by sex (i.e., 74 vs. 26% for males and 66 vs. 34% 
for females) [2]. EOP and LOP are further characterized by 
differences in genetic susceptibility loci. For instance, EOP 
has been strongly associated with human leukocyte antigen 
(HLA)-Cw6, HLA-B57, and HLA-DR7 alleles, whereas the 
HLA-Cw2 allele is overrepresented in LOP [2, 3]. Addition-
ally, patients with EOP are more likely to have a positive 
family history and require systemic therapies than are those 
with LOP [4].
As the number of options for treating psoriasis contin-
ues to grow, there is increasing focus on how clinicians 
can provide patient-directed therapies to maximize treat-
ment outcomes. One study found differences in response 
to etanercept between patients with EOP and those with 
LOP, but the study was limited by the number of treat-
ments and sample size [5]. Real-world evidence of treat-
ment outcomes in patients with EOP and LOP is lacking in 
the literature. The Psoriasis Longitudinal Assessment and 
Registry (PSOLAR) is a prospective, longitudinal, non-
interventional, disease-based registry designed to collect 
clinical and safety outcome data from patients receiving 
systemic or biologic therapies through and up to 8 years 
[6, 7]. In this study, we used PSOLAR data to examine dif-
ferences in treatment response between EOP and LOP fol-
lowing treatment with a biologic agent (i.e., adalimumab, 
etanercept, infliximab, ustekinumab) or methotrexate.
2  Methods
2.1  Study Design and Patients
The design of PSOLAR has been reported previously [6, 7]. 
Briefly, patients had to be aged ≥ 18 years and must have had 
a diagnosis of psoriasis, for which they were receiving, or 
were eligible to receive, treatment with systemic therapies 
as prescribed by their physician per actual clinical practice. 
Data (e.g., demographic and patient characteristics, clinical 
and safety outcomes, and psoriasis treatment) are collected 
every 6 months. Enrollment in PSOLAR began on 20 June 
2007, and the registry is fully enrolled (12,090 patients in 16 
countries); the data included in this analysis were collected 
through 23 August 2015. Planned follow-up for each patient 
is 8 years from the time of registry enrollment.
2.2  Ethics
The registry (ClinicalTrials.gov identifier: NCT00508547) is 
conducted in accordance with current US FDA regulations 
and guidelines, International Conference on Harmonization 
Good Clinical Practices, the principles of the Declaration of 
Helsinki, and all other applicable national and local laws and 
regulations. The study protocol was approved by an insti-
tutional review board or ethics committee at all sites, and 
written informed consent was provided by all patients before 
study procedures were initiated.
2.3  Outcome Measures
Treatment outcomes were measured based on two stand-
ard assessments of psoriasis severity: Physician’s Global 
Assessment (PGA) scores and percentage of body surface 
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area involved with psoriasis (%BSA). The PGA evaluates the 
qualitative characteristics of psoriasis lesions (i.e., indura-
tion, scaling, and erythema), resulting in a total score rang-
ing from clear (0) to severe (5).
2.4  Statistical Analyses
To be included in the analysis, patients had to have received 
systemic treatment with a biologic agent (adalimumab, 
etanercept, infliximab, or ustekinumab) or methotrexate 
within 6 months of enrollment in the registry. In addition, 
data regarding the age of psoriasis onset as well as base-
line (pretreatment) PGA scores or %BSA must have been 
recorded within the 3 months before starting therapy. Patients 
were grouped by their age of onset: EOP (age ≤ 40 years) or 
LOP (age > 40 years). The proportions of patients achiev-
ing a PGA score of 0 or 1 (PGA 0/1) or a %BSA < 3 or 
%BSA < 1 were summarized for the EOP and LOP groups 
at four post-baseline visits (i.e., 6 months, 1 year, 1.5 years, 
and 2 years) for the overall population and for each treatment 
group (etanercept, adalimumab, infliximab, ustekinumab, 
or methotrexate). Repeated-measures analysis with logis-
tic regression was used to calculate the adjusted odds ratio 
(AOR) for achieving PGA 0/1 and %BSA < 3 or %BSA < 1 
for the overall population. Similar sensitivity analyses were 
performed for each treatment group. Beyond the age-of-
onset group (EOP or LOP) variables, potential confounders 
in the modeled analyses included baseline PGA (0–1, 2–3, 
4–5) or %BSA (0–3, > 3– < 10, ≥ 10), current treatment, post-
baseline visit (6 months, 1 year, 1.5 years, 2 years), baseline 
body mass index, race, self-reported psoriatic arthritis, past 
or current smoking history, and past treatment with biologics 
(ustekinumab, adalimumab, etanercept, or infliximab), oral 
systemic agents (including methotrexate), and phototherapy.
3  Results
3.1  Patient Disposition and Characteristics
Of the 12,090 patients enrolled in the registry, 7511 were 
eligible for inclusion in this analysis. The median dura-
tion of follow-up as of the data cut-off date for this anal-
ysis was 4.17 years (maximum 8.12 years). Patients with 
EOP accounted for 72.9% (5479/7511) of the total sample 
size (Table 1). Most patients in the study population were 
enrolled at sites located in North America (88.7%) (Table 1). 
Mean age was 44.8 years in the EOP group and 60.2 years 
in the LOP group. More than half of the patients in each 
group were male (57.7% [EOP] and 52.4% [LOP]), and 
most patients were White (84.3% [EOP] and 80.8% [LOP]). 
Most patients had a diagnosis of plaque psoriasis (98.0 and 
95.9% for EOP and LOP, respectively); other diagnoses, 
which were not mutually exclusive, included guttate, eryth-
rodermic, pustular, and/or inverse psoriasis. Baseline disease 
severity for the overall population was moderate in most 
patients, as measured by PGA (53.3% had a score of 2–3) 
and %BSA (mean ± standard deviation, 11.5 ± 17.1); more 
than one-third of patients (38.5%) had a self-reported history 
of psoriatic arthritis.
In general, disease characteristics were consistent 
across the EOP and LOP groups, with a few exceptions. As 
expected, mean disease duration was higher in the EOP than 
in the LOP groups (21.8 vs. 8.3 years). A higher proportion 
of EOP than LOP patients reported a family history of pso-
riasis (47.5 vs. 36.9%) and a history of use of oral systemic 
treatment (34.8 vs. 29.3%), phototherapy (61.6 vs. 40.2%), 
and biologic agents (82.8 vs. 73.6%) for psoriasis prior to 
registry enrollment.
Overall, 37.6% of patients were exposed to ustekinumab, 
11.7% to infliximab, 18.2% to etanercept, 27.0% to adali-
mumab, and 5.5% to methotrexate. Compared with the EOP 
group, fewer patients with LOP were exposed to ustekinumab 
(40.2 vs. 30.6%) and more patients with LOP were exposed to 
methotrexate (3.6 vs. 10.5%).
3.2  Clinical Outcomes
3.2.1  Physician’s Global Assessment
There were no differences in the proportions of patients 
achieving a PGA 0/1 response at 6 months, 1 year, 1.5 years, 
and 2 years between the EOP and LOP groups (Table 2). After 
adjusting for potential confounders, patients in the LOP group 
were more likely to have achieved a PGA 0/1 response than 
those in the EOP group (AOR 1.14 [95% confidence interval 
(CI) 1.05–1.25]; p = 0.0019). Consistent results were observed 
in the sensitivity analysis of patients treated with etanercept 
(AOR 1.38 [95% CI 1.14–1.66]; p = 0.0010) or methotrexate 
(AOR 1.62 [95% CI 1.16–2.26]; p = 0.0049). Modeled findings 
for adalimumab, infliximab, or ustekinumab showed no differ-
ences in the likelihood of patients achieving PGA 0/1 between 
the EOP and LOP groups (Table 2).
3.2.2  Percent Body Surface Area
The proportions of patients achieving %BSA < 3 or %BSA < 1 
were similar for the EOP and LOP groups at 6 months, 1 year, 
1.5 years, and 2 years (Tables 3 and 4). Based on AORs, no 
significant difference in the likelihood of achieving %BSA < 3 
or %BSA < 1 was found between the EOP and LOP groups. 
However, sensitivity analyses showed that patients in the LOP 
group were more likely than those in the EOP group to achieve 
%BSA < 3 and %BSA < 1 when treated with infliximab or 
etanercept. The likelihood of LOP patients treated with inflixi-
mab achieving %BSA < 3 was 45% greater (AOR 1.45 [95% 
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Table 1  Demographic and patient characteristics at enrollment by age of onset
Data are presented as mean ± standard deviation or number of patients (%) unless otherwise indicated
BSA body surface area, EOP early-onset psoriasis, LOP late-onset psoriasis, PGA Physician Global Assessment
a Age of onset ≤ 40 years
b Age of onset > 40 years
c First therapy on registry
d Other types of psoriasis were not mutually exclusive
EOPa (n = 5479) LOPb (n = 2032) All patients (n = 7511)
Treatmentc
 Adalimumab 1479 (27.0) 549 (27.0) 2028 (27.0)
 Etanercept 952 (17.4) 415 (20.4) 1367 (18.2)
 Infliximab 648 (11.8) 232 (11.4) 880 (11.7)
 Ustekinumab 2202 (40.2) 622 (30.6) 2824 (37.6)
 Methotrexate 198 (3.6) 214 (10.5) 412 (5.5)
Age, years 44.8 ± 12.3 60.2 ± 9.0 49.0 ± 13.4
Age (years) at enrollment
 Quartile 1 (18 to < 39) 1877 (34.3) – 1877 (25.0)
 Quartile 2 (≥ 39 to < 50) 1647 (30.1) 231 (11.4) 1878 (25.0)
 Quartile 3 (≥ 50 to < 59) 1176 (21.5) 702 (34.6) 1878 (25.0)
 Quartile 4 (≥ 59) 779 (14.2) 1099 (54.1) 1878 (25.0)
Sex, male 3160 (57.7) 1064 (52.4) 4224 (56.2)
Race
 White 4618 (84.3) 1641 (80.8) 6259 (83.3)
 Black or African American 151 (2.8) 105 (5.2) 256 (3.4)
 Asian 220 (4.0) 80 (3.9) 300 (4.0)
 Hispanic or Latino 351 (6.4) 154 (7.6) 505 (6.7)
 Other 139 (2.5) 52 (2.6) 191 (2.5)
Region
 North America 4817 (87.9) 1845 (90.8) 6662 (88.7)
 Europe 601 (11.0) 154 (7.6) 755 (10.1)
 South America 61 (1.1) 33 (1.6) 94 (1.3)
Family history of psoriasis 2602 (47.5) 749 (36.9) 3351 (44.6)
 Plaque 5367 (98.0) 1949 (95.9) 7316 (97.4)
 Otherd 438 (8.0) 210 (10.3) 648 (8.6)
 Guttate 235 (4.3) 58 (2.9) 293 (3.9)
 Erythrodermic 51 (0.9) 31 (1.5) 82 (1.1)
 Pustular 55 (1.0) 76 (3.7) 131 (1.7)
 Inverse 127 (2.3) 60 (3.0) 187 (2.5)
Psoriatic arthritis, self-reported 2105 (38.4) 789 (38.8) 2894 (38.5)
PGA score
 0–1 2025 (37.0) 746 (36.7) 2771 (36.9)
 2–3 2923 (53.4) 1083 (53.3) 4006 (53.3)
 4–5 531 (9.7) 203 (10.0) 734 (9.8)
Mean BSA,  % (median) 11.5 ± 17.1 (5.0) 11.5 ± 17.2 (5.0) 11.5 ± 17.1 (5.0)
Mean duration of psoriasis, years (median) 21.8 ± 13.0 (20.5) 8.3 ± 7.2 (6.3) 18.1 ± 13.1 (16.3)
Prior treatment
 Oral systemic agents 1909 (34.8) 596 (29.3) 2505 (33.4)
 Phototherapy 3374 (61.6) 816 (40.2) 4190 (55.8)
 Biologics 4539 (82.8) 1496 (73.6) 6035 (80.3)
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CI 1.09–1.93]; p = 0.0103) and the likelihood of achieving 
%BSA < 1 was 36% greater (AOR 1.36 [95% CI 1.03–1.78]; 
p = 0.0290) than that of EOP patients. For patients treated 
with etanercept, those in the LOP group were 30% more 
likely to achieve %BSA < 3 (AOR 1.30 [95% CI 1.06–1.61]; 
p = 0.0123) and 34% more likely to achieve %BSA < 1 (AOR 
1.34 [95% CI 1.09–1.64]; p = 0.0053) than those in the EOP 
group. No difference was observed in the likelihood of achiev-
ing %BSA < 3 or %BSA < 1 for patients treated with usteki-
numab, adalimumab, or methotrexate in the EOP and LOP 
groups (Tables 3 and 4).
Table 2  Patients achieving PGA 0/1 at post-baseline visits based on age of onset
Data are presented as number of patients (%) or adjusted odds ratio (95% confidence interval)
EOP early-onset psoriasis, LOP late-onset psoriasis, PGA 0/1 Physician’s Global Assessment score of clear or minimal
Treatment Proportion of patients achieving PGA 0/1 Odds of achieving PGA 0/1
for LOP vs. EOP
At 6 months At 1 year At 1.5 years At 2 years
EOP LOP EOP LOP EOP LOP EOP LOP
Overall 2703 1009 2518 928 2282 818 2145 773 1.14 (1.05–1.25)
(56.2) (56.6) (56.6) (57.7) (56.7) 56.8) (55.7) (57.7) p = 0.0019
Adalimumab 740 266 668 250 618 223 558 208 1.09 (0.93–1.28)
(58.3) (55.3) (58.3) (59.0) (59.7) (59.6) (56.8) (58.4) p = 0.2755
Etanercept 432 209 396 185 357 169 320 153 1.38 (1.14–1.66)
(52.5) (59.4) (52.3) (56.8) (52.3) (56.9) (49.7) (55.8) p = 0.0010
Infliximab 332 134 312 113 288 105 274 96 1.15 (0.90–1.46)
(59.0) (65.7) (58.4) (61.1) (59.8) (61.8) (59.8) (65.3) p = 0.2652
Ustekinumab 1139 309 1083 312 974 261 951 253 0.99 (0.85–1.15)
(57.4) (55.5) (58.1) (60.0) (57.4) (56.7) (58.2) (58.4) p = 0.8910
Methotrexate 59 90 58 67 45 59 41 62 1.62 (1.16–2.26)
(35.1) (48.1) (38.9) (44.1) (36.0) (42.8) (31.8) (48.4) p = 0.0049
Table 3  Patients achieving %BSA < 3 at post-baseline visits based on age of onset
Data are presented as number of patients (%) or adjusted odds ratio (95% confidence interval)
BSA body surface area, EOP early-onset psoriasis, LOP late-onset psoriasis
Treatment Proportion of patients achieving %BSA < 3 Odds of achiev-
ing %BSA < 3
for LOP vs. 
EOP
At 6 months At 1 year At 1.5 years At 2 years
EOP LOP EOP LOP EOP LOP EOP LOP
Overall 2857 1026 2765 1030 2591 920 2492 890 1.08 (0.98–1.18)
(59.4) (57.6) (62.2) (64.1) (64.4) (63.9) (64.7) (66.5) p = 0.1165
Adalimumab 772 276 734 266 681 238 669 229 1.01 (0.85–1.20)
(60.8) (57.4) (64.1) (62.7) (65.8) 63.6) (68.1) (64.3) p = 0.9006
Etanercept 444 202 422 208 381 190 370 180 1.30 (1.06–1.61)
(54.0) (57.2) (55.8) (63.6) (55.8) (63.8) (57.5) (65.5) p = 0.0123
Infliximab 329 134 343 129 313 122 312 110 1.45 (1.09–1.93)
(58.4) (65.7) (64.2) (69.7) (64.9) (71.8) (68.1) (74.8) p = 0.0103
Ustekinumab 1241 325 1203 340 1159 300 1088 294 0.88 (0.75–1.04)
(62.5) (58.4) (64.5) (65.4) (68.3) (65.2) (66.5) (67.9) p = 0.1343
Methotrexate 71 89 63 87 57 70 53 77 1.27 (0.87–1.84)
(42.3) (47.6) (42.3) (57.2) (45.6) (50.7) (41.1) (60.2) p = 0.2120
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4  Discussion
Our findings are based on real-world data from 7511 
patients with psoriasis who were treated with systemic 
therapies during enrollment in PSOLAR. Treatment out-
comes were compared among EOP and LOP patients 
overall as well as among those treated with ustekinumab, 
adalimumab, etanercept, infliximab, and methotrexate at 
four time points (6 months, 1 year, 1.5 years, and 2 years). 
In this analysis, nearly three-quarters of patients (72.9%) 
had EOP, which is consistent with previously reported 
prevalence data for EOP [2, 5]. Furthermore, our results 
indicate that age of onset of psoriasis may affect how 
patients respond to systemic therapies based on measures 
of achieving PGA 0/1, %BSA < 3, or %BSA < 1 responses.
The proportions of treatment responders in the EOP and 
LOP groups were consistent across measures assessed at 
each of four time points; however, the multivariate model 
detected significant differences in response between EOP 
and LOP groups for some treatments. Across all treat-
ments combined, there was a 14% greater likelihood of 
LOP patients achieving PGA 0/1 response; however, no 
differences were observed in the proportion of patients 
achieving %BSA < 3 or %BSA < 1 responses. In contrast, 
sensitivity analyses by treatment showed that, compared 
with the EOP group, LOP patients responded better to 
etanercept, infliximab, and methotrexate. Patients in the 
LOP group who were treated with etanercept were 38, 
30, and 34% more likely than those in the EOP group to 
have responded when response was measured using PGA 
0/1, %BSA < 3, and %BSA < 1, respectively. Similarly, 
infliximab-treated patients in the LOP group were 45% 
and 36% more likely than those in the EOP group to have 
achieved %BSA < 3 and %BSA < 1 responses, respectively; 
however, no difference was observed based on achiev-
ing PGA 0/1 response. Conversely, methotrexate-treated 
patients in the LOP group were 62% more likely to have 
achieved a PGA 0/1 response, but no difference was noted 
when assessed using %BSA parameters. Therefore, our 
results for adalimumab, ustekinumab, and etanercept are 
consistent across measures and support the notion that 
adalimumab and ustekinumab are better choices than 
etanercept for treating EOP patients. The heterogeneity in 
responses between endpoints for infliximab and metho-
trexate complicate the interpretation, but the results gener-
ally suggest that these agents might be less useful for EOP 
patients than for those with LOP.
Response rates did not differ based on age of onset of 
psoriasis in patients treated with either ustekinumab or 
adalimumab. A possible explanation may be that patients 
who display different genetic susceptibility loci have vari-
able treatment responses [8]. Studies evaluating response 
to biologics in psoriasis patients treated with ustekinumab 
and adalimumab have found variable responses among 
those carrying an HLA-Cw6 allele, which is associated 
with EOP, compared with those without this haplotype 
[9–13]. Other potential differences by age of onset, such 
as antidrug antibody development and treatment compli-
ance patterns, may also have affected response rates across 
therapies.
As expected based on published literature, patients with 
EOP had a significantly greater disease duration (21.8 vs. 
Table 4  Patients achieving %BSA < 1 at post-baseline visits based on age of onset
Data are presented as number of patients (%) or adjusted odds ratio (95% confidence interval)
BSA body surface area, EOP early-onset psoriasis, LOP late-onset psoriasis
Treatment Proportion of patients achieving %BSA < 1 Odds of achiev-
ing %BSA < 1
for LOP vs. 
EOP
At 6 months At 1 year At 1.5 years At 2 years
EOP LOP EOP LOP EOP LOP EOP LOP
Overall 2238 816 2209 801 1995 713 1992 723 1.09 (1.00–1.19)
(46.5) (45.8) (49.7) (49.8) (49.6) (49.5) (51.8) (54.0) p = 0.0582
Adalimumab 621 219 597 212 545 183 538 190 1.01 (0.85–1.19)
(48.9) (45.5) (52.1) (50.0) (52.7) (48.9) (54.8) (53.4) p = 0.9379
Etanercept 319 159 324 155 282 153 281 142 1.34 (1.09–1.64)
(38.8) (45.0) (42.8) (47.4) (41.3) (51.3) (43.6) (51.6) p = 0.0053
Infliximab 279 110 275 103 247 96 257 97 1.36 (1.03–1.78)
(49.6) (53.9) (51.5) (55.7) (51.2) (56.5) (56.1) (66.0) p = 0.0290
Ustekinumab 971 257 971 273 880 229 875 239 0.93 (0.80–1.08)
(48.9) (46.1) (52.1) (52.5) (51.9) (49.8) (53.5) (55.2) p = 0.3490
Methotrexate 48 71 42 58 41 52 41 55 1.35 (0.92–1.97)
(28.6) (38.0) (28.2) (38.2) (32.8) (37.7) (31.8) (43.0) p = 0.1241
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8.3 years) and were more likely to have a positive family 
history of psoriasis (47.5 vs. 36.9%) than patients with 
LOP. Patients in the EOP group in this analysis were also 
more likely than those in the LOP group to have been 
treated previously with oral systemic agents (34.8 vs. 
29.3%) and phototherapy (61.6 vs. 40.2%). Our findings 
are consistent with reports suggesting that, compared with 
patients with LOP, those with EOP may have an increased 
need for systemic therapies, given the greater disease 
severity and longer disease duration [14].
The findings of this analysis should be considered in 
the context of its limitations. The data used to draw these 
conclusions are derived from “real-world” clinical encoun-
ters that do not necessarily adhere to structured treatment 
protocols. Inherent to this limitation is the potential for 
treatment selection bias; however, the baseline disease 
severity for the two comparator groups (EOP vs. LOP) 
was not significantly different. Additionally, the statisti-
cal model may not account for all confounding variables.
5  Conclusion
Among the 7511 patients treated with biologics or meth-
otrexate in PSOLAR, we found that age of onset may be 
associated with response to certain systemic treatments 
and may be useful for developing individualized treatments 
to maximize treatment response. Differences in responses 
between EOP and LOP patients was particularly evident for 
etanercept, infliximab, and methotrexate, suggesting those 
with LOP were more likely than those with EOP to experi-
ence a treatment response. However, the results suggested 
no difference in treatment outcomes in patients treated with 
ustekinumab or adalimumab.
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